GMDA - Gamida Cell stock falls a day after soaring on FDA lifting clinical hold on GDA-201

Shares of Gamida Cell (NASDAQ:GMDA) have fallen 8% to $2.48 in morning trade on Wednesday, a day after gaining as much as 16%. GMDA on April 26 said the U.S. Food and Drug Administration (FDA) had cleared its new drug application and lifted the clinical hold for a cryopreserved formulation of GDA-201, the company's cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas. GMDA stock had soared 32% in Tuesday premarket trading on the announcement, and had risen as much as 16% to $3.27 in the opening 10 minutes of trade. However, it then gave up all the gains through the day and ended 4.6% lower as investors priced in the news. Separately, on Wednesday, GMDA presented updated one-year post-transplant follow up data from a phase 3 study of its cell therapy omidubicel, which is under development as a potential stem cell transplant

For further details see:

Gamida Cell stock falls a day after soaring on FDA lifting clinical hold on GDA-201